Fresenius Medical Care
A global kidney-care brand providing dialysis products, therapies and renal-care services.
Last updated October 14, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Fresenius Medical Care is a German healthcare company focused on the treatment of kidney disease, especially end-stage kidney disease, also called end-stage renal disease. Its business combines the manufacture and sale of dialysis equipment and consumables with the operation of outpatient dialysis clinics and a broader portfolio of renal-care services. The company is headquartered in Bad Homburg vor der Höhe, Germany, with a major North American base in Waltham, Massachusetts. The company was created in 1996 when the dialysis activities of Germany’s Fresenius Group were combined with National Medical Care, a large U.S. dialysis provider descended from W.R. Grace’s healthcare operations. The transaction created an unusually integrated business: Fresenius Medical Care could manufacture dialysis machines, dialyzers, bloodlines, concentrates, solutions, and other supplies while also providing treatment in its own clinics. That combination remains central to the company’s competitive identity and operating model. Fresenius Medical Care primarily serves people whose kidneys can no longer adequately remove waste and excess fluid from the blood. In-center hemodialysis is the company’s largest service activity, but its portfolio also includes peritoneal dialysis, home hemodialysis, acute kidney replacement therapy, vascular-access services, clinical research, care coordination, and value-based care programs. Its home-therapy capabilities were strengthened substantially through the 2019 acquisition of NxStage Medical, whose products include portable systems for home hemodialysis and critical-care applications. As reported for fiscal year 2025, the company operated approximately 3,600 dialysis centers in more than 30 countries and treated about 291,900 patients in its own or operated network. It also maintained approximately 35 production sites in 19 countries and employed about 109,700 people. The company estimates that it provides care to roughly 7 percent of dialysis patients worldwide and holds particularly strong positions in hemodialysis machines, dialyzers, and other dialysis products. In the United States, its Fresenius Kidney Care network is one of the largest outpatient dialysis systems. The group is organized around three broad operating areas. Care Delivery encompasses dialysis clinics, home therapies, acute-care dialysis, vascular-care services, and related patient programs. Care Enablement includes machines, dialyzers, solutions, concentrates, disposables, home-dialysis systems, and products used in acute kidney replacement therapy. Value-Based Care covers programs designed to coordinate treatment and manage outcomes and costs for defined patient populations. The structure reflects a strategic shift from being primarily a dialysis-clinic operator toward being a more complete renal-care platform. The company’s growth has been shaped by acquisitions, regulation, and operational restructuring. The 2012 acquisition of Liberty Dialysis Holdings expanded its U.S. clinic network and home-dialysis capabilities, although the Federal Trade Commission required divestitures of clinics in overlapping markets. The acquisition of NxStage in 2019 broadened the company’s home-care technology portfolio. In 2023, Fresenius Medical Care changed its legal form from a partnership limited by shares to a German stock corporation, simplifying its corporate structure while retaining Fresenius SE & Co. KGaA as its major shareholder. Fresenius Medical Care has also faced substantial legal and regulatory scrutiny. In 2000, National Medical Care and related subsidiaries entered guilty pleas and civil settlements concerning allegations of unnecessary Medicare testing and illegal laboratory kickbacks, producing a combined payment of approximately $486 million. In 2019, the company agreed to pay more than $231 million to resolve U.S. Foreign Corrupt Practices Act matters involving alleged improper payments and intermediary arrangements in multiple c…
History
Fresenius Medical Care was formed in 1996 through the combination of the dialysis business of Germany’s Fresenius Group and National Medical Care, a major U.S. dialysis provider associated with W.R. Grace. The combination created an international company with both manufacturing and clinical-service capabilities. Rather than limiting itself to selling dialysis equipment or operating treatment centers, the new company pursued vertical integration across products, treatment delivery, research, and related renal services. The company’s early development was closely linked to the growth of chronic dialysis as a life-sustaining treatment for patients with severe kidney failure. Dialysis requires recurring treatment, often several times per week, and depends on a network of clinics, trained clinical staff, machines, dialyzers, fluid-management systems, vascular access, laboratory monitoring, and dependable supply chains. Fresenius Medical Care’s integrated model allowed it to serve these needs through both its own facilities and sales to external healthcare providers. A major early challenge came from the legal history of National Medical Care. In January 2000, National Medical Care and related subsidiaries resolved a wide-ranging U.S. healthcare-fraud case through guilty pleas and civil settlements. The government alleged that the organization had submitted claims for unnecessary laboratory testing and participated in illegal kickback arrangements involving laboratory business. The combined criminal and civil payment was approximately $486 million. The matter became one of the defining compliance events in the company’s history and led to continuing attention to billing controls, corporate integrity, and healthcare regulation. During the 2000s, Fresenius Medical Care expanded its global clinic and manufacturing footprint while increasing its presence in the United States. The company developed a broad product portfolio that included hemodialysis machines, dialyzers, concentrates, solutions, bloodlines, and other disposables. It also pursued adjacent renal services and forms of care coordination intended to address patient needs beyond the dialysis session itself. In 2012, Fresenius Medical Care acquired Liberty Dialysis Holdings, which included Liberty Dialysis and Renal Advantage operations. The transaction expanded the company’s U.S. outpatient clinic network and added capabilities in home dialysis. Because of competition concerns, the Federal Trade Commission required the divestiture of clinics in overlapping local markets. The acquisition and related divestitures illustrated the regulatory difficulty of expanding in a concentrated dialysis-services market. The company also broadened its laboratory and diagnostic-service activities during the 2010s. It acquired Shiel Medical Laboratory in 2013, expanding its laboratory presence in the New York metropolitan area, and later sold that business to Quest Diagnostics in 2017. The divestiture reflected a continuing effort to concentrate on renal care and businesses more closely connected to the company’s core clinical and product capabilities. Rice Powell became Chief Executive Officer and Chair of the Management Board in 2013. During his tenure, Fresenius Medical Care invested in home therapies, care coordination, digitalization, clinical research, and emerging dialysis markets. Home treatment became increasingly important as healthcare systems sought to give suitable patients more independence and, in some circumstances, reduce the intensity of facility-based care. In February 2019, Fresenius Medical Care completed the acquisition of NxStage Medical. NxStage developed portable home-hemodialysis and critical-care equipment, and its integration gave Fresenius Medical Care a stronger technology platform for home dialysis. The transaction supported the company’s effort to shift some treatment activity toward home settings and to offer patients a wider choice of therapy modalities. The year 2019 also brought a major international anti-corruption settlement. Fresenius Medical Care agreed to pay more than $231 million to resolve DOJ and SEC investigations under the U.S. Foreign Corrupt Practices Act. The matter involved alleged corrupt schemes and improper payments in multiple countries, including arrangements using third parties and sham commissions to obtain or retain business. The resolution required enhanced controls, continuing cooperation, and an independent compliance monitor. In early 2023, the company reported that the monitor had certified its compliance program and that the U.S. authorities accepted the certification. The COVID-19 pandemic highlighted the company’s role as both a treatment provider and a medical-technology manufacturer. Acute kidney injury associated with severe illness increased demand for continuous kidney replacement therapy and acute dialysis equipment. Fresenius Medical Care reported efforts to increase production and establish reserves of equipment and supplies for hospitals while maintaining treatment for chronic dialysis patients. In 2022, Helen Giza became CEO and Chair of the Management Board, succeeding Rice Powell. The company subsequently refreshed its organizational structure and management team. Martin Fischer became CFO in October 2023, and Craig Cordola joined the Management Board with responsibility for Care Delivery in January 2024. In November 2023, the company completed a legal-form conversion from a partnership limited by shares to a German stock corporation, Fresenius Medical Care AG. The conversion was intended to simplify the corporate structure and improve transparency while maintaining the strategic relationship with major shareholder Fresenius SE & Co. KGaA. The company’s recent strategy has emphasized efficiency, portfolio focus, margin improvement, digital care, home dialysis, and patient experience. The FME25 program sought to deliver structural savings and improve execution. In 2025, the company introduced FME Reignite as a new strategic framework intended to strengthen core operations, support profitable growth, and advance innovation and culture. As of fiscal year 2025, Fresenius Medical Care operated approximately 3,600 dialysis centers in more than 30 countries, served about 291,900 patients in its own or operated network, and maintained roughly 35 production sites in 19 countries. Its current business is organized around Care Delivery, Care Enablement, and Value-Based Care. The company remains a leading global dialysis provider, but its development increasingly reflects a broader ambition to manage kidney disease across products, clinics, home treatment, acute care, research, data, and coordinated patient services.
- 2026
Charles Hugh-Jones joins Management Board
[19]Charles Hugh-Jones became Global Chief Medical Officer and a Management Board member effective January 1, 2026.
- 2025
FME Reignite strategy introduced
[20]Fresenius Medical Care introduced FME Reignite to sharpen its focus on core operations, profitable growth, innovation, and organizational culture.
- 2024
FTC civil investigative demands disclosed
[10]The company disclosed that U.S. regulators were investigating possible unfair or exclusionary conduct involving medical-director services and dialysis provision.
- 2023
Anti-corruption monitor process completed
[18]The independent monitor certified the company’s anti-corruption compliance program, and the DOJ and SEC accepted the certification; the related U.S. resolutions expired in March 2023.
- 2023
Corporate-form conversion completed
[19]Fresenius Medical Care converted from a KGaA structure to a German stock corporation, becoming Fresenius Medical Care AG.
- 2022
Helen Giza becomes CEO
[17]Helen Giza was appointed Chief Executive Officer and Chair of the Management Board in December 2022.
- 2019
NxStage acquisition completed
[5]The company completed its acquisition of NxStage Medical, strengthening home hemodialysis and critical-care device capabilities.
- 2019
Foreign bribery settlement
[7]Fresenius Medical Care reached a U.S. DOJ and SEC resolution involving alleged FCPA violations and agreed to monetary penalties, compliance enhancements, and independent monitoring.
- 2017
Shiel laboratory business sold
[16]Fresenius Medical Care sold Shiel Medical Laboratory to Quest Diagnostics.
- 2013
Rice Powell becomes CEO
[15]Rice Powell became Chair and Chief Executive Officer of the Management Board.
Products and positioning
A vertically integrated, premium-scale global renal-care leader combining dialysis products, outpatient treatment, home therapies, and care-delivery services.
Dialysis equipment
Hemodialysis machines
Fresenius Medical Care develops and manufactures machines used to perform in-center and home hemodialysis. These systems control blood flow, dialysate delivery, ultrafiltration, monitoring, alarms, and treatment parameters. The company’s installed base supports its own clinic network and sales to external providers. Hemodialysis machines are a central component of the Care Enablement business and one of the company’s strongest global product categories.
Dialysis consumables
Dialyzers
Dialyzers, sometimes called artificial kidneys, filter waste products and excess fluid from a patient’s blood during hemodialysis. Fresenius Medical Care produces a broad range of dialyzers using different membrane technologies and configurations for clinical applications. The products are used in the company’s own centers and sold to hospitals, clinics, and other healthcare providers worldwide.
Dialysis consumables
Dialysis solutions and concentrates
Dialysis solutions and concentrates provide the fluid chemistry required for hemodialysis. Fresenius Medical Care manufactures concentrates, premixed solutions, and related products for use with dialysis machines. The portfolio supports chronic in-center treatment, home therapies, and acute-care applications, and forms part of the company’s vertically integrated supply chain.
Home dialysis
Peritoneal dialysis products
The company provides products for peritoneal dialysis, a home-based therapy that uses the patient’s peritoneal membrane as a natural filter. The portfolio includes fluid solutions, tubing, connectors, and systems designed to support continuous ambulatory or automated peritoneal dialysis. These products extend the company’s renal-care offering beyond conventional in-center hemodialysis.
Home dialysis equipment · 2019
NxStage home hemodialysis systems
NxStage systems are portable hemodialysis technologies designed for home use and, in some configurations, critical-care settings. Fresenius Medical Care acquired NxStage in 2019 and integrated its products into the company’s home-therapy strategy. The platform is intended to give suitable patients greater flexibility and independence while enabling providers to support home treatment through training, logistics, and clinical monitoring.
Acute-care equipment
Acute kidney replacement therapy systems
Fresenius Medical Care supplies systems and consumables for acute kidney injury and continuous kidney replacement therapy in hospitals and intensive-care settings. These products are used when patients require temporary dialysis because of acute kidney failure, severe illness, or other conditions. The portfolio includes machines, solutions, and disposables designed for continuous or intermittent acute treatments.
Dialysis services · 2012
Fresenius Kidney Care
Fresenius Kidney Care is the company’s principal U.S. service brand for kidney disease education, in-center dialysis, home dialysis, and related patient support. It operates a large network of outpatient centers and provides clinical, nutritional, educational, and care-coordination resources. The brand is also used to support patient transitions toward home hemodialysis and peritoneal dialysis when clinically appropriate.
Renal-care services
Vascular-care services
Fresenius Medical Care provides vascular-access services for dialysis patients, including evaluation and treatment related to the access points needed for hemodialysis. The company has operated vascular-care businesses in the United States, including outpatient services associated with dialysis access management. Vascular care is strategically adjacent to dialysis delivery but has also been the subject of regulatory and litigation scrutiny.
Medical devices
Dialysis machines
Equipment used to conduct dialysis treatments by supporting the extracorporeal circulation of blood and the removal of waste products and excess fluid. The supplied materials identify dialysis equipment as a core part of the brand’s medical-technology portfolio, but do not specify individual models or launch dates.
Renal-care consumables
Dialyzers and dialysis consumables
Specialized disposable components and consumables used in dialysis treatment, including dialyzers that support the filtering process. They form part of the broader treatment ecosystem supplied to dialysis providers and healthcare institutions. Specific product families and regulatory markets are not identified in the supplied references.
Healthcare service and therapy
Chronic kidney dialysis
Renal replacement therapy for patients requiring continuing treatment because of chronic kidney failure. Fresenius Medical Care is described as providing both the products used in dialysis and related care services, linking clinical treatment delivery with its medtech portfolio.
Healthcare service and therapy
Acute kidney dialysis
Dialysis and related extracorporeal treatment for acute-care settings, where kidney support may be required during serious illness or hospitalization. The official reference identifies acute dialysis as one of the organization’s principal therapy areas, without specifying particular products or service locations.
Blood-treatment technology
Therapeutic apheresis
Extracorporeal blood-treatment procedures that separate or remove selected blood components for therapeutic purposes. The official website lists therapeutic apheresis alongside chronic and acute dialysis, indicating that the brand’s scope extends beyond kidney replacement therapy.
Controversies
2025
Proposed dialysis-price antitrust class action
A benefits fund filed a proposed class action alleging that Fresenius and DaVita coordinated to restrict competition, allocate markets, and inflate outpatient dialysis prices. The claims remain allegations in pending litigation.
2024
FTC investigation into possible exclusionary conduct
The company disclosed an FTC investigation involving possible unfair or exclusionary conduct in the acquisition of medical-director services or the provision of dialysis services. The investigation concerned regulatory scrutiny rather than a final finding of liability.
2022
Fresenius Vascular Care False Claims Act allegations
The U.S. government alleged that Fresenius Vascular Care performed certain vascular procedures on dialysis patients without sufficient clinical indication and billed public and private healthcare programs. The case was a civil complaint and the allegations were not treated as a final adjudication.
2021
Fresenius Medical Care faces allegations over Malawi dialysis contracts
A Nyasa Times report said Fresenius Medical Care faced criticism in Malawi over an alleged effort to gain control of dialysis services and alleged corrupt practices related to government contracts. The allegations were reported, not established as findings in this article.
2019
Foreign Corrupt Practices Act settlement
U.S. authorities alleged that Fresenius entities used improper payments, third-party arrangements, and sham commissions to obtain or retain business in multiple countries. The company agreed to pay more than $231 million and accept independent compliance monitoring and other controls.
2000
Medicare testing and laboratory kickback case
National Medical Care and related subsidiaries pleaded guilty and entered civil settlements over allegations involving unnecessary laboratory testing, false claims, and illegal kickbacks for laboratory business. The combined criminal and civil resolution was approximately $486 million.
Marketing campaigns
- 2025FME Reignite
Global
FME Reignite was introduced as the company’s strategic framework for strengthening core operations, improving profitable growth, supporting innovation, and advancing company culture.
Outcome. The strategy became the company’s principal post-FME25 platform for operational and commercial renewal.
- 2023Connected kidney care and AI initiatives
Global
Fresenius Medical Care advanced digitalization, connected-care tools, and the use of large clinical datasets to support treatment monitoring, research, and patient management.
Outcome. The company presented digital and data capabilities as part of its transition toward more personalized and technology-enabled renal care.
- 2020National Intensive Renal Care Reserve
United States
During the COVID-19 pandemic, Fresenius Medical Care organized a U.S. reserve of acute dialysis machines and supplies to support hospitals treating patients with severe illness and acute kidney injury.
Outcome. The initiative supported hospital preparedness while the company expanded acute-product manufacturing and maintained chronic dialysis operations.
- 2019Path to Home
United States · International
The company promoted home dialysis through investments in training facilities, education, distribution infrastructure, and the integration of NxStage technology.
Outcome. Home hemodialysis became a more prominent part of the company’s service and product strategy, supported by the NxStage acquisition.
- 2012Fresenius Kidney Care launch
United States
Fresenius Medical Care launched Fresenius Kidney Care as a U.S. division focused on kidney-disease education, dialysis services, and support for people across the renal-care pathway.
Outcome. The brand became a major consumer-facing and clinical-services identity for the company’s U.S. dialysis network.
Brand decisions
2025
Introduce FME ReigniteStrategyBackground
After the FME25 transformation program, the company sought to build a more focused operating model emphasizing profitable growth, innovation, and stronger execution.
Action taken
Fresenius Medical Care introduced FME Reignite as its strategic framework for renewing the core business, improving patient care, and creating sustainable value.
Aftermath
The strategy became the company’s central platform for post-transformation growth and operational improvement.
- DaVita — No specific competitor reaction was identified in the cited materials.
2025
Expand high-volume hemodiafiltration in the United StatesProduct launchBackground
The company identified high-volume hemodiafiltration and advanced treatment modalities as areas for clinical innovation and U.S. market development.
Action taken
Fresenius Medical Care highlighted the introduction and expansion of high-volume hemodiafiltration in the United States as a 2025 innovation priority.
Aftermath
The initiative positioned advanced hemodiafiltration as part of the company’s effort to improve treatment options and clinical outcomes.
- DaVita — No specific competitor reaction was identified in the cited materials.
2023
Convert corporate legal form to German stock corporationStrategyBackground
Fresenius Medical Care sought to simplify its legal and governance structure and improve transparency for shareholders and other stakeholders.
Action taken
The company converted from a KGaA structure to Fresenius Medical Care AG, a German stock corporation, in November 2023.
Aftermath
The conversion preserved continuity in management and the company’s relationship with major shareholder Fresenius SE & Co. KGaA while creating a simpler corporate form.
- DaVita — No specific competitor reaction was identified in the cited materials.
2019
Acquire NxStage MedicalM&ABackground
Home dialysis was becoming a larger strategic priority, and NxStage offered portable home hemodialysis and critical-care technologies.
Action taken
Fresenius Medical Care completed the acquisition of NxStage Medical in February 2019 and began integrating its products, manufacturing, supply chain, and commercial capabilities.
Aftermath
The acquisition strengthened the company’s home-hemodialysis portfolio and supported a less facility-dependent treatment model.
Approximate transaction value. Approximately $2 billion (2017-2019)
- DaVita — No specific competitor reaction was identified in the cited materials.
2019
Enhance anti-corruption compliance programOtherBackground
The FCPA resolution identified weaknesses and alleged misconduct involving third parties, payments, and business acquisition practices in multiple countries.
Action taken
Fresenius Medical Care agreed to enhance internal controls, continue cooperation with U.S. authorities, and retain an independent compliance monitor.
Aftermath
The monitor certified the compliance program in early 2023, and the associated U.S. agreements expired in March 2023.
Total monetary resolution. More than $231 million (2019)
- DaVita — No specific competitor reaction was identified in the cited materials.
2012
Acquire Liberty Dialysis HoldingsM&ABackground
Fresenius Medical Care sought to expand its U.S. outpatient dialysis network and strengthen home-dialysis capabilities through the acquisition of Liberty Dialysis Holdings.
Action taken
The company completed the acquisition while agreeing to divest clinics in overlapping local markets under an FTC settlement.
Aftermath
The transaction expanded the company’s clinic and patient base but demonstrated the antitrust constraints associated with consolidation in U.S. outpatient dialysis.
Approximate transaction value. Approximately $2.1 billion proposed transaction value (2011-2012)
- DaVita — No specific competitor reaction was identified in the cited materials.
Recent events
Humacyte and Fresenius Medical Care expand partnership[23]
Reported:
Humacyte and Fresenius Medical Care expanded their strategic partnership to include vascular trauma repair outside the United States. Fresenius Medical Care will adopt Humacyte's HAV as a standard of care for patients who may benefit clinically and economically.
Fresenius Medical Care faces allegations over Malawi dialysis contracts[22]
Reported:
A Nyasa Times report said Fresenius Medical Care faced criticism in Malawi over an alleged effort to gain control of dialysis services and alleged corrupt practices related to government contracts. The allegations were reported, not established as findings in this article.
Spearwood dialysis clinic adds home dialysis training rooms[24]
Reported:
Fresenius Medical Care expanded its Fresenius Kidney Care Spearwood clinic in Perth, adding three home dialysis training rooms. The new facilities were officially opened at a ceremony on 24 October 2019.
Sources24 sources
- 1Fresenius Medical Care, Annual Report 2025freseniusmedicalcare.com
- 2Fresenius Medical Care investor FAQfreseniusmedicalcare.com
- 3Fresenius Medical Care company historyfreseniusmedicalcare.com
- 4Fresenius Medical Care contact and headquarters informationfreseniusmedicalcare.com
- 5Fresenius Medical Care completes NxStage acquisitionfreseniusmedicalcare.com
- 6U.S. Department of Justice: 2000 National Medical Care settlementjustice.gov
- 7U.S. Department of Justice: 2019 FCPA resolutionjustice.gov
- 8U.S. Department of Justice: Fresenius Vascular Care False Claims Act allegationsjustice.gov
- 9Federal Trade Commission: Liberty Dialysis acquisition divestituressearch.ftc.gov
- 10Fresenius Medical Care Form 6-K on FTC investigationfreseniusmedicalcare.com
- 11Fresenius Medical Care 2025 annual-report overviewfreseniusmedicalcare.com
- 12UFCW 1776 antitrust litigation docketdockets.justia.com
- 13Fresenius Medical Care official websitefreseniusmedicalcare.com
- 14https://www.freseniusmedicalcare.comfreseniusmedicalcare.com
- 15Rice Powell becomes CEOfreseniusmedicalcare.com
- 16Shiel Medical Laboratory acquireden.wikipedia.org
- 17Helen Giza becomes CEOfreseniusmedicalcare.com
- 18Anti-corruption monitor process completedfreseniusmedicalcare.com
- 19Corporate-form conversion completedfreseniusmedicalcare.com
- 20FME Reignite strategy introducedfreseniusmedicalcare.com
- 21National Intensive Renal Care Reservefreseniusmedicalcare.com
- 22Fresenius Medical Care faces allegations over Malawi dialysis contractsnyasatimes.com
- 23Humacyte与Fresenius Medical Care扩大合作finance.yahoo.com
- 24Spearwood透析诊所新增居家透析培训室ibtimes.com.au
Cite this profile: Cite the canonical profile. /brand-wiki/fresenius-medical-care · Editorial policy · How profiles are compiled